Detalhe da pesquisa
1.
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison.
Biometrics
; 80(1)2024 Jan 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38364811
2.
Current issues in dose-finding designs: A response to the US Food and Drug Adminstrations's Oncology Center of Excellence Project Optimus.
Clin Trials
; : 17407745241234652, 2024 Apr 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38570906
3.
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
Lancet Oncol
; 24(12): 1387-1398, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38039992
4.
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.
Biometrics
; 79(3): 2458-2473, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35974457
5.
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials.
Clin Trials
; : 17407745231214750, 2023 Dec 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38111231
6.
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Clin Trials
; 20(5): 486-496, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37313712
7.
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint.
Pharm Stat
; 22(1): 34-44, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35851545
8.
Generalized phase I-II designs to increase long term therapeutic success rate.
Pharm Stat
; 22(4): 692-706, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37038957
9.
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
Biometrics
; 78(1): 60-71, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33438761
10.
Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis.
Cancer
; 127(8): 1228-1237, 2021 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33306202
11.
Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.
Stat Med
; 40(24): 5199-5217, 2021 10 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34636054
12.
An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.
Biometrics
; 76(1): 304-315, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31273750
13.
Comparing Bayesian early stopping boundaries for phase II clinical trials.
Pharm Stat
; 19(6): 928-939, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32720462
14.
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III.
Biometrics
; 75(2): 371-381, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30367457
15.
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 24(8): 1602-1609, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29501779
16.
A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups.
Biometrics
; 74(3): 1095-1103, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29359314
17.
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
Pharm Stat
; 17(6): 734-749, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30112806
18.
A decision-theoretic phase I-II design for ordinal outcomes in two cycles.
Biostatistics
; 17(2): 304-19, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26553915
19.
A simulation study of outcome adaptive randomization in multi-arm clinical trials.
Clin Trials
; 14(5): 432-440, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28982263
20.
Bayesian variable selection for a semi-competing risks model with three hazard functions.
Comput Stat Data Anal
; 112: 170-185, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29033478